<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959907</url>
  </required_header>
  <id_info>
    <org_study_id>01-CBED06</org_study_id>
    <nct_id>NCT00959907</nct_id>
  </id_info>
  <brief_title>Comparison of Two Commercial Preparations of Botulinum Toxin Type A</brief_title>
  <official_title>A Phase iv Controlled Randomized Blinded Study on the Anhydrotic Action Halos and Muscle Activity of Two Commercial Preparations Type a Botulinum Toxin (Dysport® and Botox® ) Administered to the Upper Third of the Face</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilan Center for Studies in Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilan Center for Studies in Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the action halos of the botulinum toxins (Dysport®
      and Botox®) using two equivalence-ratios and to gather supportive information, such as more
      detailed data on the effectiveness in reduction of wrinkles and duration of action on the
      upper part of the face of both products, trough scales and photographs evaluations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a monocentric, prospective, randomized and double-blind study. Fifty nine female
      patients, presenting with moderate to severe forehead wrinkles, with sweating ability who had
      never undergone previous BoNT-A injections were enrolled. There were two randomizations, one
      related to the dose-equivalence (2:1U and 2.5:1U), both reconstituted in the same volume of
      0.02 mL per point and another related to the forehead side (left or right) for application of
      the tested drugs. Baseline, twenty-eight and 112 days later, clinical and photographic
      assessments, Minor´s test, and electromyographic (EMG) evaluations were performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Horizontal Action Halo Diameter at 28 Days</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECMAP in m. Frontialis BoNT A1(4U) X BoNT A2 (2U)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Horizontal Action Halo Diameter at 112 Days</measure>
    <time_frame>112 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Wrinkles in Frontal Area</condition>
  <arm_group>
    <arm_group_label>BoNT A1 (4U)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BoNT A1 (4U): Botulinum toxin A (Dysport®)4 units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BoNT-A2 (2U)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BoNT-A2(2U): Botulinum toxin A (Botox®) 2 units</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTULINUM TOXIN TYPE-A</intervention_name>
    <description>On Visit 1 (Day 0):
Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.
Dysport®: 4 units will be injected in the left or right forehead side.
Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)</description>
    <arm_group_label>BoNT A1 (4U)</arm_group_label>
    <arm_group_label>BoNT-A2 (2U)</arm_group_label>
    <other_name>BoNT A1 = Dysport</other_name>
    <other_name>BoNT A2 = Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written Informed Consent (Annex 1)

          2. Female

          3. Subjects agreeing to take part in all procedures of the study, including botulinum
             toxin applications, Minor's test, measurement of Evoked Potentials, photographs,
             etc.), after being fully informed on the objectives and nature of the investigations

          4. Subjects aged between 18 and 60 years

          5. Subjects presenting with moderate to severe wrinkles on the forehead under maximum
             voluntary contraction of the m. frontalis

          6. Subjects with positive Minor's test showing sweating on the forehead in standardized
             conditions described in Annex 2

             *The Minor's Test will be the last inclusion criterion to be evaluated. Only these
             patients eligible according to the other inclusion criteria will undergo the Minor's
             Test to evaluate their sweating on the forehead. The cut off point is a positive
             Minor's Test (Level +1) - only subjects with Minor's Test (Level +1) will be recruited
             in the study (Annex 2).

          7. Medical history and physical examination which, based on the investigator's opinion,
             do not prevent the patient from taking part in the study and use the products under
             investigation

          8. Subjects of childbearing age should present a negative urine pregnancy test at
             baseline and should be using an effective contraceptive method;

          9. Availability of the patient throughout the duration of the study (112 days)

         10. Subject agrees not to undergo other cosmetic or dermatological procedures during the
             study

         11. Subjects with sufficient schooling and awareness to enable them to cooperate to the
             degree required by this protocol

        Exclusion Criteria:

          1. Pregnant women or women intending to become pregnant in the next 4 months after
             screening for eligibility

          2. Subjects who are lactating

          3. Subjects having undergone botulinum toxin treatment within the last 6 months

          4. Subjects participating in other clinical trials

          5. Any prior surgery affecting the frontalis and/or orbicularis muscles, prior
             blepharoplasty or brow lift

          6. Any prior cosmetic procedures, including fillers, or scars that may interfere with the
             study results

          7. Subjects presenting fronto-parietal alopecia according to the Norwood-Hamilton
             classification

          8. Subjects with neoplastic, muscular or neurological diseases

          9. Subjects using aminoglycoside and penicillamine antibiotics, quinine and Ca2+ channel
             blockers

         10. Subjects with inflammation or active infection in the area to be injected

         11. Subjects presenting evident facial asymmetry

         12. Subjects with a history of adverse effects, such as sensitivity to the components of
             the formula, ptosis or any other adverse effect, which in the investigator's opinion
             should prevent the patient from participating in the study

         13. Subjects presenting myasthenia gravis, Eaton-Lambert Syndrome and motor neuron
             diseases

         14. Subjects with coagulation disorders or using anticoagulants

         15. Subjects with known systemic autoimmune diseases

         16. Subjects with a history of medical treatment non-adherence or showing unwillingness to
             adhere to the study protocol

         17. Any condition that, in the opinion of the investigator, can compromise the evaluation
             of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris Hexsel, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Brazilian Center for Dermatological Studies</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90570-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <results_first_submitted>April 23, 2009</results_first_submitted>
  <results_first_submitted_qc>July 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2009</results_first_posted>
  <last_update_submitted>December 9, 2009</last_update_submitted>
  <last_update_submitted_qc>December 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Doris Hexsel</name_title>
    <organization>CBED</organization>
  </responsible_party>
  <keyword>Muscular activity</keyword>
  <keyword>wrinkles in frontal area</keyword>
  <keyword>action halos</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment process: It is planned to recruit a total of 58 subjects at one single centre, Brazilian Center For Studies in Dermatology, in Porto Alegre, Brazil. The anticipated drop out rate is 10%.
Baseline evaluation: May 2005 to July 2007.</recruitment_details>
      <pre_assignment_details>13 volunteers were excluded; (screen failure) Iodine allergy=2 Minor´s Test failure=6 Mild wrinkles=3 Inclusion criteria failure=2</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BoNT A1(4U)</title>
          <description>Group 1: Botulinum toxin A (Dysport®) will be administered 4 units of Dysport®</description>
        </group>
        <group group_id="P2">
          <title>BoNT-A2(2U)</title>
          <description>Group 2: Botulinum toxin A (Botox®) will be administered 2 units of Botox®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BoNT A1(4U)</title>
          <description>Group 1: Botulinum toxin A (Dysport®) will be administered 4 units of Dysport®</description>
        </group>
        <group group_id="B2">
          <title>BoNT-A2(2U)</title>
          <description>Group 2: Botulinum toxin A (Botox®) will be administered 2 units of Botox®</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.77" spread="8.67"/>
                    <measurement group_id="B2" value="41.86" spread="11.98"/>
                    <measurement group_id="B3" value="42.88" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Horizontal Action Halo Diameter at 28 Days</title>
        <description>Minor’s test permits the visualization of the effect of botulinum toxin in the injected area,also called action halos. Mirror is a computer program that allows, through photogrpahs, measuring the horizontal diameter and the area of action halos.</description>
        <time_frame>28 days</time_frame>
        <population>The analysis was intention to treat (ITT); One drop out, from baseline to visit 1(intervention) and 3 drop outs from visit 1 to visit 2 (28 days after botulinum toxin injections). Started 59 volunteers - 4 drop outs, there was 55 volunteers in the first analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>BoNT A1(4U)</title>
            <description>Group 1: Botulinum toxin A (Dysport®) will be administered 4 units of Dysport®</description>
          </group>
          <group group_id="O2">
            <title>BoNT-A2(2U)</title>
            <description>Group 2: Botulinum toxin A (Botox®) will be administered 2 units of Botox®</description>
          </group>
        </group_list>
        <measure>
          <title>Horizontal Action Halo Diameter at 28 Days</title>
          <description>Minor’s test permits the visualization of the effect of botulinum toxin in the injected area,also called action halos. Mirror is a computer program that allows, through photogrpahs, measuring the horizontal diameter and the area of action halos.</description>
          <population>The analysis was intention to treat (ITT); One drop out, from baseline to visit 1(intervention) and 3 drop outs from visit 1 to visit 2 (28 days after botulinum toxin injections). Started 59 volunteers - 4 drop outs, there was 55 volunteers in the first analysis.</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0526" spread="0.3638"/>
                    <measurement group_id="O2" value="1.0670" spread="0.2239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.832</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECMAP in m. Frontialis BoNT A1(4U) X BoNT A2 (2U)</title>
        <description>ECMAP(Evoked Compound Muscle Action Potentials) was accessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BoNT A1(4U)</title>
            <description>Group 1: Botulinum toxin A (Dysport®) will be administered 4 units of Dysport®</description>
          </group>
          <group group_id="O2">
            <title>BoNT-A2(2U)</title>
            <description>Group 2: Botulinum toxin A (Botox®) will be administered 2 units of Botox®</description>
          </group>
        </group_list>
        <measure>
          <title>ECMAP in m. Frontialis BoNT A1(4U) X BoNT A2 (2U)</title>
          <description>ECMAP(Evoked Compound Muscle Action Potentials) was accessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).</description>
          <units>microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.18" spread="319.15"/>
                    <measurement group_id="O2" value="289.00" spread="303.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.658</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.739</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Horizontal Action Halo Diameter at 112 Days</title>
        <description>Minor’s test permits the visualization of the effect of botulinum toxin in the injected area,also called action halos. Mirror is a computer program that allows, through photogrpahs, measuring the horizontal diameter and the area of action halos.</description>
        <time_frame>112 days</time_frame>
        <population>Intention to treat analysis. 55 volunteers - One drop out from visit 2 (28 days) to visit 3 (112 days): 54 volunteers.</population>
        <group_list>
          <group group_id="O1">
            <title>BoNT A1(4U)</title>
            <description>Group 1: Botulinum toxin A (Dysport®) will be administered 4 units of Dysport®</description>
          </group>
          <group group_id="O2">
            <title>BoNT-A2(2U)</title>
            <description>Group 2: Botulinum toxin A (Botox®) will be administered 2 units of Botox®</description>
          </group>
        </group_list>
        <measure>
          <title>Horizontal Action Halo Diameter at 112 Days</title>
          <description>Minor’s test permits the visualization of the effect of botulinum toxin in the injected area,also called action halos. Mirror is a computer program that allows, through photogrpahs, measuring the horizontal diameter and the area of action halos.</description>
          <population>Intention to treat analysis. 55 volunteers - One drop out from visit 2 (28 days) to visit 3 (112 days): 54 volunteers.</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8742" spread="0.3333"/>
                    <measurement group_id="O2" value="1.1196" spread="0.2620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.184</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BoNT A1(4U)</title>
          <description>Group 1: Botulinum toxin A (Dysport®) will be administered 4 units of Dysport®</description>
        </group>
        <group group_id="E2">
          <title>BoNT-A2(2U)</title>
          <description>Group 2: Botulinum toxin A (Botox®) will be administered 2 units of Botox®</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.15</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The field of muscular effects of the studied toxins was objectively measured by EMG and it is not very precise. However, there is no more precise objective measurement to currently evaluate the field effects in muscles than EMG.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Débora Zechmeister do Prado</name_or_title>
      <organization>CBED</organization>
      <phone>55 51 30262633</phone>
      <email>cbed@cbed.org.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

